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Background. Postoperative recurrence of the liver hydatid disease befalls approximately
1030% of patients. Preoperative or postoperative therapy with albendazole in single thera-
peutic protocol (800 mg/d, within 28 days) indicated the need to evaluate the hydatid cyst liq-
uid protoscoleces viability. Morphological changes of protoscoleces following the treatment
with drugs are not well known. Aim. To estimate the viability of protoscoleces after preopera-
tive or postoperative albendazole therapy, and their ability for cystic metamorphosis. Meth-
ods. A prospective, randomized clinical trial included 30 patients with liver hydatid disease,
treated with albendazole and surgically (I group), and 30 patients in the control group treated
only surgically (II group). The concentration of albendazole and its active metabolite alben-
dazole sulphoxide in the cysts contents were determined using HPLC. Estimation of protosco-
leces viability was based on the established micromorphologic criteria, and compared be-
tween the patients treated with albendazole, and the patients treated only surgically. Biologi-
cal assessment of the viability was performed on protoscoleces with uncertain signs of the
disturbed viability (unchanged structure, evaginated, without movements) using intraperito-
neal injection of 1 ml of protoscoleces prepared suspension to AO type of rats. Results. The
concentration of albendazole in cysts' contents ranged from 0 to 64.9 μg/ml, and of its active
metabolite from 0.5 to 40.8 μg/ml. The presence of fully viabile protoscoleces in the alben-
dazol treated patients was significantly lower than in the control group. A significant differ-
ence was noticed in the presence of disintegrated protoscoleces without movements in the al-
bendazol treated group, compared to the control group. Biological assessment of the viability
showed incapability of these protoscoleces for cystic metamorphoses. Conclusion. Low vi-
ability of parasites due to medicamentous therapy is very useful and important to surgeons,
because the fertility of cysts is lower, and the risk of the disease recurrence is reduced.
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Itroduction
Cystic hydatid disease is a widespread human infec-
tion caused by the larval stage of the taeniid tapeworm
Echinococcus granulosus. The disease is well known in
rural areas of Serbia and Montenegro. Surgery is still the
treatment of choice (1, 2). According to the WHO guide-
lines for the medicamentous treatment of hydatidosis, one
of the important indications for chemotherapy is the pre-
vention of secondary echinococcosis (3). Hepatic hydati-
dosis represents 10–30% of the disease recurrence after
the surgery (48). Spillage of protoscoleces (PS) during
the surgery is apparently an important cause of the recur-
rence (9). Recurrent disease can be a major clinical prob-
lem (10), and the subsequent reoperations are associated
with progressive increase in complications and higher
mortality rate (11).
The viability of PS in hydatid cysts is unknown before
its surgical removal. The use of albendazole (ABZ) to re-
duce the biological activity of the parasite in the cystic
stage, provides new therapeutical perspectives, especially in
the cases of the abdominal localisation (12).       176                              3
The aim of this study was to analyze the percentage of
viable PS and PS in various stages of degeneration in the
hydatid cysts removed during surgery, as well as their abil-
ity to metamorphose into cysts after the ABZ therapy.
Methods
The prospective, randomized clinical trial, which in-
cluded 60 patients with liver hydatid disease, was per-
formed at the Clinic for General and Vascular surgery,
Military Medical Academy, Belgrade.
The first group included 30 patients, treated preopera-
tively with ABZ 400 mg/twice a day, for 28 days. In the sec-
ond, control group, 30 patients were only surgically treated.
The concentrations of the ABZ and albendazole active me-
tabolite albendazole sulphoxide (ABZ-SO) in the cysts' con-
tents were determined using HPLC (13).
The viability of PS was assessed using direct micro-
scopic examination of the contents from the extirpated liver
hydatid cysts.
The biological assessment of PS viability was performed
in the cases with uncertain viability signs (unchanged PS
structure, evaginated, without movements). The assessment
was not performed either on PS with normal structure, and
with the signs of movements  viable PS, in the cases of dis-
integrated PS (edema, destruction of tegmentum, and defor-
mation of hooklets' row), or in the cases of cysts with only
free hooks of PS. The content of hydatid cysts (PS and germi-
nal layer), from the surgicaly treated patients was washed and
accumulated. One ml of that suspension was intraperitoneally
inoculated to the male AO type rats, aged 68 weeks, under
aseptic conditions. Six months after the inoculation, the ani-
mals were sacrificed, and the intraperitoneal sites checked for
the secondary cysts of Echinococcus granulosus.
The follow-up was conducted for 24 months for all the
patients including indirect hemaglutination and ELISA
tests, ultrasound abdominal scanning, every 3 months, and
computerized tomography once a year.
Results
No adverse drug effects during ABZ therapy were ob-
served.
In all the patients of the first group, ABZ-SO was
found in the cyst contents. The concentration of ABZ in the
hydatid contents ranged from 0 to 64.9 μg/ml, and of ABZ –
SO from 0.5 to 40.8 μg/ml. PS showed prominent morpho-
logical changes up to the disintegration. Micromorphologi-
cal characteristics of PS in both groups are shown in Table
1. Vital PS and PS in various stages of degeneration are
shown in Figures 1, 2, and 3.
The signs of intraperitoneal parasite development were
not found in the animals.
Fig. 1  Vital PS, a) invaginated, b) evaginated, rich with
glicogene and with a row of hooks. PS like this is showing
ameboid movements.
Postoperative follow-up demonstrated no recurrence of
the disease in the first group, and the patients were consid-
ered cured after 24 months.
In the second group, there were recurrences of the dis-
ease in 3 patients, who had preoperative multiple cysts or
hepatic cysts with irregular cavities that communicated
among themselves.
Table 1
Micromorphological characteristics of protoscoleces
Group II Group I
Microscopic findings
n = 30 % n = 30 %
Alive PS*, normal structure, with sings of movements 7 23.3 1 3.3
Vital, evaginated PS*, unchanged structure, without movements 8 26.6 18 60.0
Disintegrated PS (edema, destruction of tegmentum, deformation
of hooklets row)
8 26.6 9 30.0
Free hooks of PS* 7 23.3 2 6.6
* Statistically significant II : I p<0.05
a)
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Fig. 2  Disintegrated, avital PS (destruction of tegmentum,
deformation of hooks row, does not have glicogene, is losing
some number of hooks, not showing movements).
Discussion
Frequent usage of benzoimidazolic drugs for the
treatment of human hydatidosis indicated the need for the
assessment of hydatid contents viability in order to lessen
the risk of secondary echinococcosis. Thus, testing of hyda-
tid cysts contents viability after the surgical removal was
important for subsequent medicamentous treatment, and for
the assessment of the risk of the disease recurrence (14).
The patophysiological mechanism of ABZ-SO effect
on PS in human hydatid cysts, however, hasn't been re-
vealed yet.
The viability of the cysts can be determined by the
presence of PS in various stages of degeneration. This
method was frequently used. The absence of parasite
growth in the experimental animals should be used as the
final criteria. However, the presence of viable PS does not
necessarily indicate the eventual development of secondary
echinococcosis, which is more likely to appear after the
surgery, when it is obligatory to check for them (14).
In order to determine more precisely the ABZ effects
on the treated patients, we compared some basic PS viabil-
ity parameters in the patients treated with ABZ, with pa-
rameters in the patients surgically treated. We analyzed the
percentage of completely vital PS in both groups, and di-
vided the cases with vital PS and unchanged structure from
the minimal signs of disturbed viability. The hydatid con-
tents of PS were assessed using intraperitoneal inoculation
of AO rats. We expected that the completely vital PS, intra-
peritoneally applied by El Mufti et al. (15) would result in
cystic metamorphosis but in the case of disintegrated PS we
could not expect a positive biological answer.
In our study, all the patients in the first group were
found to be with the presence of ABZ-SO in all cysts. The
presence of the fully viabile PS in the ABZ treated patients
was significantly lower than in the the control group. Also,
the significant difference between the two groups of pa-
tients was found in the presence of disintegrated PS without
movements. Biological check of viability using intraperito-
Fig. 3  Total disintegrated PS with free hooks of E. granulosus
in a smear obtained from liquid cyst content.       178                              3
neal inoculation to AO rats showed similar incapability for
cystic metamorphosis. The average percentage value of vi-
abile PS in the cysts according to Pappalardo et al. in the
patients treated with mebendazole was 31.1%, which was
significantly lower than in the patients treated only surgi-
cally, and was up to 70%. In addition, the tendency of PS to
develop cyst in inoculated BALB/c mice is lower than that
of PS obtained from the cysts of the patients who were only
surgically treated (5).
Rahemtulla et al. (16) also inoculated six experimental
animals intraperitoneally 28 days with suspension (0.5 ml) of
PS and germinal epithelium. After 11 months, the signs of
parasite development were not found. The studies on the effi-
cacy of preoperative ABZ therapy in primary disease indi-
cated the possibility of reducing the number of viable PS in
the treated cysts (17). Ayles et al. (18) concluded that the pre-
operative medical therapy reduced significantly the number of
cysts that contain viable PS. It was also possible to make an
algorithm for the management of the patients with hydatid
disease with chemotherapy and surgery, yet the assessment of
the results using indirect techniques was still difficult.
Our findings, as well as the findings of the other
authors, suggested that the lower viability of parasite was
the result of medicamentous therapy. The results like these
are significant for a surgeon, since they allow him to oper-
ate smaller fertile cysts, reducing significantly the risk of
intraoperative dissemination caused by the planned and/or,
especially, undesirable rupture of cysts. Under these condi-
tions, when PS were, first treated with drugs, and under un-
favorable metabolic conditions, according to Papparaldo et
al. (5), they were not capable of metamorphosis. It was
identical to our micromorphological research on PS and to
the results of biological viability check.
Conclusion
Significantly lower PS viability in the group of pa-
tients preoperatively treated with ABZ was found, using
both microscopic examination of the hydatid cysts contents
and biological check of the material. At the same time, the
investigation of hydatid cysts contents, in the control group
showed a significant number of completely vital PS. In the
intraoperatively obtained hydatid cysts contents in patients
treated with ABZ, the concentration of ABZ-SO (active
metabolite) was 0–40.8  g/ml. The obtained concentration
was below the level of minimal therapeutic concentration,
under in vitro conditions. Considering the effects of ABZ
therapy, it could be speculated that concentrations of this
metabolite could also be found under in vivo conditions.
Based on the obtained results, it could be concluded that the
use of ABZ 800 mg/day within 28 days, was sufficient to
achieve the therapeutic drug level under in vivo conditions.
Low viability of PS due to medicamentous treatment is
very useful and important for surgeons, because fertile cysts
are smaller the risk of undesirable cysts rupture is lower,
and the risk of the disease recurrence is reduced.
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EHINOKOKUSNO OBOLJENJE JETRE: MORFOLOŠKE PROMENE
PROTOSKOLEKSA POSLE LE ENJA ALBENDAZOLOM
Cilj. Recidiv ehinokokusnog oboljenja jetre posle hirurškog le enja javlja se kod
1030% bolesnika. Preoperativna ili postoperativna primena jednog ciklusa le enja
albendazolom (800 mg dnevno, tokom 28 dana) uslovila je potrebu za procenom
vitalnosti protoskoleksa hidatidnog sadržaja. Malo se zna o morfološkim promena-
ma protoskoleksa posle medikamentoznog le enja. Cilj ove studije bio je procena
vitalnosti protoskoleksa nakon preoperativnog le enja albendazolom, kao i njihove
sposobnosti da se pretvore u cistu. Metode. Prospektivno, randomizovano klini ko
ispitivanje sprovedeno je kod 30 bolesnika sa ehinokokusnim oboljenjem jetre, le-
 enih albendazolom i hirurški (I grupa) i 30 bolesnika le enih samo hirurški (II gru-
pa). Koncentracija albendazola i njegovog aktivnog metabolita albendazol sulfoksi-
da u sadržaju cisti odre ivana je metodom te ne hromatografije pod visokim pritis-
kom. Procena vitalnosti protoskoleksa vršena je po utvr enim mikromorfološkim
kriterijumima kod bolesnika koji su le eni medikamentozno u odnosu na bolesnike
koji nisu medikamentozno le eni. Biološka provera protoskoleksa sa nesigurnim
znacima vitalnosti (nepromenljive gra e, evaginovani i nepokretni) vršena je intra-
peritoneumskim ubrizgavanjem 1 ml suspenzije protoskoleksa pacovima OA inbre-
dnog soja. Rezultati. Koncentracija albendazola u sadržaju ehinokokusnih cisti iz-
nosila je od 0 do 64,9 μg/ml, a njegovog aktivnog metabolita od 0,5 do 40,8 μg/ml.
Zastupljenost potpuno vitalnih protoskoleksa u I grupi bolesnika, le enih medika-
mentozno, bila je zna ajno smanjena u odnosu na II, kontrolnu grupu. Tako e je
utvr ena zna ajna razlika u pogledu zastupljenosti evaginovanih, nepokretnih pro-
toskoleksa u grupi le enoj albendazolom u odnosu na kontrolnu grupu bolesnika.
Biološka provera ovih protoskoleksa pokazala je da oni nisu sposobni da se pretvo-
re u cistu. Zaklju ak. Zaklju eno je da je smanjena vitalnost protoskoleksa posle-
dica medikamentozne terapije, što je veoma važno za hirurga, jer su ciste koje ope-
riše manje fertilne a opasnost od recidiva bolesti manja.
K lj u   n e   r e   i : jetra, parazitne bolesti; ehinokokoza jetre;
albendazol; hirurgija, operativna, procedure;
mikroskopija; hromatografija, te na, pod vp;  elija,
preživljavanje; recidiv.
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